This study will assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer.
- Metastatic Hormone Sensitive Prostate Cancer
- Within 12 weeks of starting ADT
There is a screening period of 4 weeks to assess suitability for the trial. This is a randomised study with a ratio of 2:1 received the study therapy. While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.